Skip to main content
. 2009 Jul 17;284(38):25984–25992. doi: 10.1074/jbc.M109.016808

FIGURE 1.

FIGURE 1.

Treatment of mice with a CAR agonist inhibited obesity. A, growth curve (A, a), fat mass/body weight ratio (A, b), and lean mass/body weight ratio (A, c) in male C57BL/6J mice fed with HFD for 5 weeks, in the absence or presence of TCPOBOP treatment (0.5 mg/kg, intraperitoneal, once per week). Fat and lean masses were determined by MRI. n = 5 for each group. B, a representative pair of vehicle- and TCPOBOP-treated mice in A. C, body weight and body composition of mice at the end of a 5-week diet and drug treatment. D, serum levels of bile acids (left) and ALT activity (right) at the end of an 8-week diet and drug treatment. E, growth curve (E, a) and fat mass/body weight ratio (E, b) in female C57BL/6J mice prefed with HFD for 6 weeks followed by 6 weeks of TCPOBOP treatment during which the mice remained on HFD. n = 5 for each group. F, gain of fat mass in female ob/ob mice maintained on a chow diet treated with vehicle or TCPOBOP for 8 weeks (0.5 mg/kg, once per week). n = 5 for each group. G, body weight and body composition of ob/ob mice at the end of the 8-week drug treatment. Results are expressed as means ± S.D. *, p < 0.05; **, p < 0.01, compared with the vehicle group.